Literature DB >> 4024269

Prophylactic effect in mice of BCG vaccination against nontuberculous mycobacterial infections.

I M Orme, F M Collins.   

Abstract

The effect of prior vaccination of mice with Mycobacterium bovis BCG on the subsequent course of acute aerogenic infection with various environmental mycobacteria was tested. A protective effect was recorded against infection with M. avium, and M. kansasii; by contrast no effect was noted against M. simiae or M. intracellulare. The prophylactic effects of BCG were demonstrated regardless of whether vaccination was given by the intravenous or aerogenic routes. These findings support the hypothesis that BCG vaccination, if given prior to contact, can provide some degree of protection against certain non-tuberculous mycobacterial infections.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4024269     DOI： 10.1016/0041-3879(85)90076-5

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


  14 in total

1.  Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection.

Authors:  E Martin; J A Triccas; A T Kamath; N Winter; W J Britton
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Serovars of Mycobacterium avium complex isolated from patients in Sweden.

Authors:  S E Hoffner; G Källenius; B Petrini; P J Brennan; A Y Tsang
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

3.  Protection against virulent Mycobacterium avium infection following DNA vaccination with the 35-kilodalton antigen is accompanied by induction of gamma interferon-secreting CD4(+) T cells.

Authors:  E Martin; A T Kamath; J A Triccas; W J Britton
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein.

Authors:  M Velaz-Faircloth; A J Cobb; A L Horstman; S C Henry; R Frothingham
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

Review 5.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

6.  Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia.

Authors:  Kathleen England; Christopher am Ende; Hao Lu; Todd J Sullivan; Nicole L Marlenee; Richard A Bowen; Susan E Knudson; Dennis L Knudson; Peter J Tonge; Richard A Slayden
Journal:  J Antimicrob Chemother       Date:  2009-09-04       Impact factor: 5.790

Review 7.  Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome.

Authors:  F M Collins
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

8.  Coinfection is an important factor in epidemiological studies: the first serosurvey of the aoudad (Ammotragus lervia).

Authors:  M G Candela; E Serrano; C Martinez-Carrasco; P Martín-Atance; M J Cubero; F Alonso; L Leon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-11-20       Impact factor: 3.267

9.  Crossprotection against nontuberculous mycobacterial infections by Mycobacterium tuberculosis memory immune T lymphocytes.

Authors:  I M Orme; F M Collins
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

Review 10.  BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.

Authors:  Alok K Singh; Mihai G Netea; William R Bishai
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.